Skip to main content
Article thumbnail
Location of Repository

Curr Infect Dis Rep (2010) 12:423–429 DOI 10.1007/s11908-010-0129-9 Recent Advances in the Treatment of Mucormycosis

By Brad Spellberg, Ashraf S. Ibrahim, B. Spellberg and A. S. Ibrahim

Abstract

# The Author(s) 2010. This article is published with open access at Springerlink.com Abstract In recent years, substantial advances have been achieved in the treatment of mucormycosis. It is now clear that early initiation of therapy results in substantially better outcomes, underscoring the need to maintain a high index of suspicion and aggressively biopsy potential lesions. Increasing data support the need for surgical excision of infected and/or necrosed tissue whenever feasible. Based on their superior safety and efficacy, lipid formulations of amphotericin B have become the standard treatment for mucormycosis. Posaconazole may be useful as salvage therapy, but cannot be recommended as primary therapy for mucormycosis based on available data. Pre-clinical and limited retrospective clinical data suggest that combination therapy with lipid formulations of amphotericin and an echinocandin improves survival during mucormycosis. A definitive trial is needed to confirm these results. The use of the iron chelator, deferasirox, as adjunctive therapy also improved outcomes in animal models of mucormycosis. However, its efficacy was not confirmed in a recent, phase 2 clinical trial. Additional study is required of the potential for abrogation of iron acquisition as adjunctive treatment o

Year: 2010
OAI identifier: oai:CiteSeerX.psu:10.1.1.351.9588
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://citeseerx.ist.psu.edu/v... (external link)
  • ftp://ftp.ncbi.nlm.nih.gov/pub... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.